Impact of myeloid leukemia associated mutations (ASXL1, DNMT3A, TET2, IDH1 and IDH2) on treatment responses among Chronic Myeloid Leukemia (CML) patients in Tanzania
粒细胞白血病相关突变(ASXL1、DNMT3A、TET2、IDH1 和 IDH2)对坦桑尼亚慢性粒细胞白血病 (CML) 患者治疗反应的影响
基本信息
- 批准号:10846461
- 负责人:
- 金额:$ 10.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:ABL1 geneAddressAdministrative SupplementAfrica South of the SaharaAfricanAgeAllyAwardBulky DiseaseCaringCessation of lifeChronic DiseaseChronic Myeloid LeukemiaCollaborationsCountryCross-Sectional StudiesDNMT3aDevelopmentDiagnosisDisease ProgressionDisease remissionDisparityDoctor of PhilosophyEpigenetic ProcessEquationEuropeanFinancial HardshipFoundationsGeneral PopulationGenesGeneticGenomic DNAGenomic InstabilityGoalsGuidelinesHealthHematologic NeoplasmsHematopoietic NeoplasmsHigh PrevalenceImatinibIncomeLeadLesionLife ExpectancyMalignant NeoplasmsMedicalMentorsMentorshipModelingMolecularMolecular AbnormalityMutationMyelogenousMyeloid LeukemiaNewly DiagnosedOceansOncologyOutcomeParentsPatientsPopulationPrecision therapeuticsPrevalenceProspective, cohort studyProtein Tyrosine KinaseQuality of lifeReportingResearchResearch PersonnelResistanceResource-limited settingResourcesRiskScienceSurvival RateTanzaniaTestingTimeTrainingTranslatingTreatment FailureTyrosine Kinase InhibitorUniversitiesadvanced diseasecancer carecare deliverycost effectivecost effective treatmentdeterminants of treatment resistanceevidence baseexperiencehigh riskimprovedinterestinternational partnershipleukemiamolecular diagnosticsmutational statusnext generation sequencingpatient assistanceprognosticprognostic significanceprogramsresponsesextherapy resistanttreatment guidelinestreatment response
项目摘要
ABSTRACT
This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-
23-038. The development of tyrosine kinase inhibitors (TKIs), such as imatinib, for the treatment of chronic
myeloid leukemia (CML) has dramatically improved patients’ life expectancy. In high-income nations, the life
expectancy of a patient with CML approaches that of the general population. While high-income countries are
moving towards a treatment paradigm that allows for TKI discontinuation in the setting of complete remission,
these same outcomes are unfortunately not observed in Tanzania, despite good access of TKIs to CML
patients through an established patient assistance program. Our group has previously shown that delayed
diagnoses and presentations with advanced disease features contribute to the observed poor responses
among patients with CML in Tanzania. Recent studies have shown that late CML diagnosis is associated with
cumulative accumulation of more genetic lesions which can subsequently lead to treatment failure, disease
progression, and eventual death. These mutations are most commonly identified in epigenetic modifier genes
such as ASXL1, DNMT3A, TET2, IDH1, and IDH2. We hypothesize that the poor treatment responses
observed in CML patients in Tanzania is due to a high burden of these myeloid leukemia mutations at the time
of diagnosis. Therefore, this study aims to better understand mechanisms of TKI resistance contributed by
these myeloid-associated mutations. We will conduct a prospective cohort study of newly diagnosed CML
patients followed over a period of 12 months after imatinib initiation at Ocean Road Cancer Institute in Dar es
Salaam, Tanzania. Presence of myeloid-leukemia associated mutations (ASXL1, DNMT3A, TET2, IDH1, and
IDH2) will be assessed at diagnosis. Extracted genomic DNA (gDNA) will undergo next generation sequencing
using commercially available myeloid leukemia panel on MiSeq (Illumina, San Diego, USA). Generalized
Estimating Equations (GEE) will be used to investigate the influence of mutation status at diagnosis on
molecular responses in the first 12 months of treatment as defined by the European Leukemia Net Guidelines.
Other variables including sex, age, and Sokal score at diagnosis will be considered as covariates in the model.
Identification of predictors of treatment resistance has a high potential to improve CML treatment guidelines in
Tanzania and sub-Saharan Africa broadly, based on scientific evidence derived from African population.
摘要
本申请是为了回应被确认为非CA-CA的特殊利益通知(NOSI)而提交的
23-038.酪氨酸激酶抑制剂(TKIs),如伊马替尼,治疗慢性前列腺癌的进展
髓系白血病(CML)极大地延长了患者的预期寿命。在高收入国家,生活
慢性粒细胞白血病患者的期望值接近普通人群。而高收入国家
转向允许在完全缓解的情况下停止TKI的治疗范例,
不幸的是,坦桑尼亚没有观察到同样的结果,尽管TKI很好地获得了CML
通过既定的患者援助计划为患者提供帮助。我们的小组此前已经表明,延迟
具有高级疾病特征的诊断和表现导致观察到的不良反应
在坦桑尼亚的慢性粒细胞白血病患者中。最近的研究表明,慢性粒细胞白血病的晚期诊断与
累积更多的遗传损伤,这可能随后导致治疗失败、疾病
进展,并最终死亡。这些突变最常见于表观遗传修饰基因。
例如ASXL1、DNMT3A、TET2、IDH1和IDH2。我们假设不良的治疗反应
在坦桑尼亚的CML患者中观察到的是由于当时这些髓系白血病突变的高负担
诊断的结果。因此,本研究旨在更好地了解TKI的抗性机制。
这些髓系相关突变。我们将对新诊断的慢性粒细胞白血病进行前瞻性队列研究。
达累斯海路癌症研究所的患者在伊马替尼开始治疗后12个月内进行了随访
坦桑尼亚的萨拉姆。存在髓系白血病相关突变(ASXL1、DNMT3A、TET2、IDH1和
IDH2)将在诊断时进行评估。提取的基因组DNA(GDNA)将进行下一代测序
在MiSeq(美国圣地亚哥Illumina)上使用商业上可用的髓系白血病面板。泛化
将使用估计方程(GEE)来研究诊断时突变状态对
根据欧洲白血病网络指南的定义,治疗前12个月的分子反应。
其他变量,包括性别、年龄和确诊时的Sokal评分,将被视为模型中的协变量。
识别治疗耐药的预测因素对改进CML治疗指南具有很高的潜力
坦桑尼亚和撒哈拉以南非洲,根据从非洲人口中得出的科学证据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ahlam Nasser其他文献
Ahlam Nasser的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 10.96万 - 项目类别:
Research Grant